Does Cardiac MRI Evaluate Patent Foramen Ovale and Atrial Septal Defect?
Yes, cardiac MRI can evaluate both PFO and ASD, but it serves different roles for each: it is a Class I recommendation for comprehensive ASD evaluation (anatomy, shunt quantification, and hemodynamic impact), while for PFO it has limited utility and is inferior to echocardiography for diagnosis. 1
Atrial Septal Defect Evaluation
CMR should be used for the evaluation of the magnitude and direction of intracardiac shunts in children and adults with ASDs (Class I, Level of Evidence B). 1 The 2022 Society for Cardiovascular Magnetic Resonance guidelines establish CMR as a primary imaging modality for ASD assessment, offering several key advantages:
Anatomic Delineation
- CMR provides definitive diagnosis and evaluation of sinus venosus defects and anomalous pulmonary venous connections, which are difficult to image with echocardiography, particularly in older patients 1
- Comprehensive evaluation of secundum ASDs can determine candidacy for transcatheter versus surgical closure 1
- 3D imaging may be useful for delineating complex or multiple defects 1
Shunt Quantification
CMR offers multiple methods for calculating Qp/Qs (pulmonary-to-systemic flow ratio):
- Phase-contrast flow measurements in the aorta and pulmonary artery
- Ventricular stroke volume calculations (though this requires knowledge of shunt location and valve competence) 1
- Research demonstrates excellent correlation with invasive oximetry (r=0.91, p<0.0001) 2
Hemodynamic Assessment
- Accurate measurement of ventricular volumes and function to evaluate physiological sequelae (e.g., RV volume loading in ASD) 1
- Assessment of biventricular size and function 3
- Detection of associated anomalies, notably anomalous pulmonary venous drainage 3
Patent Foramen Ovale Evaluation
For PFO, CMR has significant limitations and is inferior to transesophageal echocardiography (TEE). The evidence consistently shows:
Limited Diagnostic Accuracy
- CMR detected contrast-enhanced right-to-left shunting in only 66.6% of cases with moderate-to-severe shunts on TEE, and just 18.8% of mild shunts 4
- CMR is inferior to TEE for detecting ASA (37.3% vs 62.7% detection rate) 4
- While one pilot study showed feasibility with good correlation (r=0.7), it acknowledged the need for further investigation 5
Clinical Context
PFO evaluation typically requires:
- Contrast-enhanced transthoracic or transesophageal echocardiography with Valsalva maneuver remains the method of choice 6
- Transcranial Doppler is often used in conjunction with echocardiography 6
- CMR may have a role in excluding other cardiac anomalies (coronary anomalies, venous returns) when comprehensive cardiac assessment is needed 4
Practical Algorithm
For ASD:
- Use CMR when echocardiography is insufficient (older patients, poor acoustic windows)
- Obtain phase-contrast flow measurements for Qp/Qs calculation
- Assess ventricular volumes and function for hemodynamic impact
- Evaluate for anomalous pulmonary venous drainage
- Use findings to determine transcatheter versus surgical candidacy
For PFO:
- Start with contrast-enhanced echocardiography (TTE or TEE) with Valsalva
- Reserve CMR only when comprehensive cardiac evaluation is needed to exclude other pathology
- Do not rely on CMR for PFO diagnosis or shunt grading
- Use TEE for pre-procedural planning if closure is considered
Important Caveats
- Ventricular stroke volume calculations require knowledge of shunt location: An ASD produces RV stroke volume twice the LV stroke volume, while a VSD produces the opposite pattern 1
- Valve competence is essential for accurate Qp/Qs calculation using ventricular volumes 1
- Multiple CMR methods should be used in the same patient for internal quality assurance 1
- The 2010 European guidelines 3 support CMR for questions remaining after echocardiography regarding shunt amount, biventricular function, and associated anomalies